The University of Chicago Header Logo

Connection

Michael Charlton to Male

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Male.
Michael Charlton
Connection Strength
1.761
Male
  1. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 10; 10(10):1198-1208.
    View in: PubMed
    Score: 0.041
  2. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.041
  3. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol. 2020 Jul; 55(7):722-730.
    View in: PubMed
    Score: 0.038
  4. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
    View in: PubMed
    Score: 0.032
  5. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017 Jun 01; 312(6):G666-G680.
    View in: PubMed
    Score: 0.031
  6. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.030
  7. Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med. 2016 04 28; 374(17):1688.
    View in: PubMed
    Score: 0.029
  8. Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit. Gastroenterology. 2016 Feb; 150(2):306-9.
    View in: PubMed
    Score: 0.028
  9. Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver Int. 2015 Dec; 35(12):2625.
    View in: PubMed
    Score: 0.028
  10. Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret. Hepatology. 2015 Nov; 62(5):1337-8.
    View in: PubMed
    Score: 0.028
  11. Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice. Gastroenterology. 2015 Sep; 149(3):531-4.
    View in: PubMed
    Score: 0.027
  12. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.027
  13. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.027
  14. Reply: To PMID 24824965. Hepatology. 2015 Apr; 61(4):1442-3.
    View in: PubMed
    Score: 0.027
  15. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol. 2015 Aug; 110(8):1126-33.
    View in: PubMed
    Score: 0.027
  16. Chronic kidney disease (CKD) and NAFLD: time for awareness and screening. J Hepatol. 2015 Apr; 62(4):983-4.
    View in: PubMed
    Score: 0.026
  17. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.026
  18. Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology. 2014 Sep; 60(3):815-22.
    View in: PubMed
    Score: 0.026
  19. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20(7):791-7.
    View in: PubMed
    Score: 0.025
  20. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014 Jun; 14(6):1383-90.
    View in: PubMed
    Score: 0.025
  21. Decreased muscle mass in nonalcoholic fatty liver disease: new evidence of a link between growth hormone and fatty liver disease? Hepatology. 2014 May; 59(5):1668-70.
    View in: PubMed
    Score: 0.025
  22. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View in: PubMed
    Score: 0.024
  23. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr; 60(4):691-8.
    View in: PubMed
    Score: 0.024
  24. Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. J Hepatol. 2014 Jan; 60(1):6-8.
    View in: PubMed
    Score: 0.024
  25. The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States. Am J Transplant. 2013 Nov; 13(11):2794-6.
    View in: PubMed
    Score: 0.024
  26. Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Liver Transpl. 2013 Aug; 19(8):787-9.
    View in: PubMed
    Score: 0.024
  27. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod. Am J Transplant. 2013 Jul; 13(7):1633-5.
    View in: PubMed
    Score: 0.024
  28. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring). 2013 Sep; 21(9):1935-41.
    View in: PubMed
    Score: 0.024
  29. ChREBP in NASH - a liver transcription factor comes in from the cold. J Hepatol. 2013 Jul; 59(1):178-9.
    View in: PubMed
    Score: 0.023
  30. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View in: PubMed
    Score: 0.022
  31. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012 Jul 27; 94(2):197-203.
    View in: PubMed
    Score: 0.022
  32. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18(7):803-10.
    View in: PubMed
    Score: 0.022
  33. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18(3):323-31.
    View in: PubMed
    Score: 0.022
  34. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
    View in: PubMed
    Score: 0.022
  35. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012 Feb; 32(2):279-86.
    View in: PubMed
    Score: 0.021
  36. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141(4):1249-53.
    View in: PubMed
    Score: 0.021
  37. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View in: PubMed
    Score: 0.021
  38. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011 Mar; 21(3):310-5.
    View in: PubMed
    Score: 0.020
  39. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011 Jan; 53(1):317-24.
    View in: PubMed
    Score: 0.020
  40. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 2011 Jan; 17(1):23-31.
    View in: PubMed
    Score: 0.020
  41. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology. 2011 Jan; 140(1):25-8.
    View in: PubMed
    Score: 0.020
  42. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View in: PubMed
    Score: 0.019
  43. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7.
    View in: PubMed
    Score: 0.019
  44. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
    View in: PubMed
    Score: 0.018
  45. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology. 2009 Apr; 49(4):1375-84.
    View in: PubMed
    Score: 0.018
  46. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
    View in: PubMed
    Score: 0.017
  47. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008 Mar; 8(3):667-72.
    View in: PubMed
    Score: 0.016
  48. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008 Feb; 47(2):484-92.
    View in: PubMed
    Score: 0.016
  49. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
    View in: PubMed
    Score: 0.015
  50. Perioperative viral kinetics: new insights or the Emperor's new clothes? Liver Transpl. 2006 Feb; 12(2):194-5.
    View in: PubMed
    Score: 0.014
  51. Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis? Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):72-3.
    View in: PubMed
    Score: 0.014
  52. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.013
  53. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 2003 Jul; 38(1):244-51.
    View in: PubMed
    Score: 0.012
  54. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
    View in: PubMed
    Score: 0.011
  55. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.011
  56. Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs. Hepatol Commun. 2021 11; 5(11):1953-1963.
    View in: PubMed
    Score: 0.010
  57. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001 Jul; 7(7):608-14.
    View in: PubMed
    Score: 0.010
  58. Simultaneous Heart-Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes. Hepatology. 2021 04; 73(4):1464-1477.
    View in: PubMed
    Score: 0.010
  59. Impact of nutritional status on outcomes after liver transplantation. Transplantation. 2000 Nov 15; 70(9):1347-52.
    View in: PubMed
    Score: 0.010
  60. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
    View in: PubMed
    Score: 0.010
  61. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation. 2000 Jul 27; 70(2):292-7.
    View in: PubMed
    Score: 0.010
  62. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020 09 01; 319(3):G333-G344.
    View in: PubMed
    Score: 0.010
  63. The effect of insulin on human small intestinal mucosal protein synthesis. Gastroenterology. 2000 Feb; 118(2):299-306.
    View in: PubMed
    Score: 0.009
  64. Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. J Heart Lung Transplant. 2019 09; 38(9):997-999.
    View in: PubMed
    Score: 0.009
  65. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
    View in: PubMed
    Score: 0.009
  66. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.009
  67. Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes. 1998 Nov; 47(11):1748-56.
    View in: PubMed
    Score: 0.009
  68. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
    View in: PubMed
    Score: 0.009
  69. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
    View in: PubMed
    Score: 0.008
  70. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology. 1998 Sep; 28(3):839-42.
    View in: PubMed
    Score: 0.008
  71. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018 11; 155(5):1463-1473.e6.
    View in: PubMed
    Score: 0.008
  72. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol. 2018 09; 69(3):617-625.
    View in: PubMed
    Score: 0.008
  73. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018 Mar 28; 24(12):1321-1331.
    View in: PubMed
    Score: 0.008
  74. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
    View in: PubMed
    Score: 0.008
  75. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
    View in: PubMed
    Score: 0.008
  76. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
    View in: PubMed
    Score: 0.008
  77. Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? Transplantation. 1998 Jan 15; 65(1):73-6.
    View in: PubMed
    Score: 0.008
  78. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
    View in: PubMed
    Score: 0.008
  79. Skeletal muscle myosin heavy chain synthesis in type 1 diabetes. Diabetes. 1997 Aug; 46(8):1336-40.
    View in: PubMed
    Score: 0.008
  80. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997 Jul; 3(4):359-64.
    View in: PubMed
    Score: 0.008
  81. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.008
  82. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.007
  83. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah. Dig Dis Sci. 2016 12; 61(12):3627-3632.
    View in: PubMed
    Score: 0.007
  84. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.007
  85. Evidence for a catabolic role of glucagon during an amino acid load. J Clin Invest. 1996 Jul 01; 98(1):90-9.
    View in: PubMed
    Score: 0.007
  86. Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
    View in: PubMed
    Score: 0.007
  87. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.007
  88. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.007
  89. Obesity is independently associated with infection in hospitalised patients with end-stage liver disease. Aliment Pharmacol Ther. 2015 Dec; 42(11-12):1271-80.
    View in: PubMed
    Score: 0.007
  90. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015 Sep 02; 15:371.
    View in: PubMed
    Score: 0.007
  91. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 May; 21(5):599-606.
    View in: PubMed
    Score: 0.007
  92. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May; 61(5):1485-94.
    View in: PubMed
    Score: 0.007
  93. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21(2):248-57.
    View in: PubMed
    Score: 0.007
  94. A randomized, prospective, parallel group study of laparoscopic versus laparoendoscopic single site donor nephrectomy for kidney donation. Am J Transplant. 2014 Jul; 14(7):1630-7.
    View in: PubMed
    Score: 0.006
  95. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc. 2014 May; 89(5):595-601.
    View in: PubMed
    Score: 0.006
  96. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66.
    View in: PubMed
    Score: 0.006
  97. Early MRI in term infants with perinatal hypoxic-ischaemic brain injury: interobserver agreement and MRI predictors of outcome at 2 years. Clin Radiol. 2014 Jan; 69(1):72-81.
    View in: PubMed
    Score: 0.006
  98. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013 Aug; 19(8):887-95.
    View in: PubMed
    Score: 0.006
  99. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26(8):788-94.
    View in: PubMed
    Score: 0.006
  100. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.006
  101. Hepatic artery pseudoaneurysm formation following intraductal biliary radiofrequency ablation. Endoscopy. 2013; 45 Suppl 2 UCTN:E161-2.
    View in: PubMed
    Score: 0.006
  102. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8.
    View in: PubMed
    Score: 0.006
  103. Introduction to the genetics and biology of interleukin-28B. Hepatology. 2012 Jul; 56(1):361-6.
    View in: PubMed
    Score: 0.006
  104. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
    View in: PubMed
    Score: 0.005
  105. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci. 2012 Apr; 57(4):952-7.
    View in: PubMed
    Score: 0.005
  106. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.005
  107. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg. 2011 Nov; 21(11):1714-20.
    View in: PubMed
    Score: 0.005
  108. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011 Aug; 52(8):1517-25.
    View in: PubMed
    Score: 0.005
  109. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.005
  110. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010 Dec; 20(12):1698-709.
    View in: PubMed
    Score: 0.005
  111. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
    View in: PubMed
    Score: 0.005
  112. Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
    View in: PubMed
    Score: 0.005
  113. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009 Jul 27; 88(2):219-25.
    View in: PubMed
    Score: 0.005
  114. Asynchronous, out-of-sequence, transcontinental chain kidney transplantation: a novel concept. Am J Transplant. 2009 Sep; 9(9):2180-5.
    View in: PubMed
    Score: 0.004
  115. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol. 2007 Dec; 157(6):1183-8.
    View in: PubMed
    Score: 0.004
  116. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
    View in: PubMed
    Score: 0.004
  117. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27; 83(12):1639-42.
    View in: PubMed
    Score: 0.004
  118. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007 Mar; 5(3):394-402; quiz 267.
    View in: PubMed
    Score: 0.004
  119. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006 Sep; 12(9):1381-9.
    View in: PubMed
    Score: 0.004
  120. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005 Oct; 11(10):1207-13.
    View in: PubMed
    Score: 0.003
  121. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol. 2005 Apr; 100(4):874-8.
    View in: PubMed
    Score: 0.003
  122. Hypophosphatemia after right hepatectomy for living donor liver transplantation. Can J Gastroenterol. 2004 Dec; 18(12):729-33.
    View in: PubMed
    Score: 0.003
  123. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002 Oct 15; 35(8):974-81.
    View in: PubMed
    Score: 0.003
  124. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol. 2002 Jun; 167(6):2408-12.
    View in: PubMed
    Score: 0.003
  125. Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol. 2002 Jun; 97(6):1472-5.
    View in: PubMed
    Score: 0.003
  126. Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol. 2002 Apr; 33(4):435-6.
    View in: PubMed
    Score: 0.003
  127. Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes. 2001 Dec; 50(12):2652-8.
    View in: PubMed
    Score: 0.003
  128. Insulin's effect on synthesis rates of liver proteins. A swine model comparing various precursors of protein synthesis. Diabetes. 2001 May; 50(5):947-54.
    View in: PubMed
    Score: 0.003
  129. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001 Apr; 7(4):302-10.
    View in: PubMed
    Score: 0.003
  130. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000 Feb; 163(2):524-7.
    View in: PubMed
    Score: 0.002
  131. Clinical significance of TT virus infection in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Oct; 94(10):3020-7.
    View in: PubMed
    Score: 0.002
  132. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999 Apr; 29(4):1050-6.
    View in: PubMed
    Score: 0.002
  133. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
    View in: PubMed
    Score: 0.002
  134. Cancer in young people in the north of England, 1968-85: analysis by census wards. J Epidemiol Community Health. 1993 Apr; 47(2):109-15.
    View in: PubMed
    Score: 0.001
  135. Endoscopic therapy for bile duct stones in a geriatric population. Postgrad Med J. 1992 Jun; 68(800):457-60.
    View in: PubMed
    Score: 0.001
  136. Factors influencing mortality and morbidity following oesophageal resection. Eur J Cardiothorac Surg. 1989; 3(5):419-23; discussion 424.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.